Cibc Asset Management Inc Vaxcyte, Inc. Transaction History
Cibc Asset Management Inc
- $28 Billion
- Q4 2024
A detailed history of Cibc Asset Management Inc transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Cibc Asset Management Inc holds 3,307 shares of PCVX stock, worth $292,074. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,307
Previous 3,136
5.45%
Holding current value
$292,074
Previous $358,000
24.58%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding PCVX
# of Institutions
357Shares Held
123MCall Options Held
772KPut Options Held
430K-
Vanguard Group Inc Valley Forge, PA11.4MShares$1.01 Billion0.02% of portfolio
-
Janus Henderson Group PLC London, X010.9MShares$965 Million0.67% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$878 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$767 Million13.83% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.9MShares$433 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $5.24B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...